Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F24%3A10478669" target="_blank" >RIV/00064165:_____/24:10478669 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/24:10478669
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=sNW2L4.lHL" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=sNW2L4.lHL</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s11883-024-01191-w" target="_blank" >10.1007/s11883-024-01191-w</a>
Alternative languages
Result language
angličtina
Original language name
Increased Cardiovascular Risk in Young Patients with CKD and the Role of Lipid-Lowering Therapy
Original language description
Purpose of Review: Chronic kidney disease (CKD) is associated with a significantly increased risk of cardiovascular disease (CVD). This review summarizes known risk factors, pathophysiological mechanisms, and current therapeutic possibilities, focusing on lipid-lowering therapy in CKD. Recent Findings: Novel data on lipid-lowering therapy in CKD mainly stem from clinical trials and clinical studies. Summary: In addition to traditional CVD risk factors, patients with CKD often present with non-traditional risk factors that include, e.g., anemia, proteinuria, or calcium-phosphate imbalance. Dyslipidemia remains an important contributing CVD risk factor in CKD, although the mechanisms involved differ from the general population. While statins are the most commonly used lipid-lowering therapy in CKD patients, some statins may require dose reduction. Importantly, statins showed diminished beneficial effect on cardiovascular events in patients with severe CKD and hypercholesterolemia despite high CVD risk and effective reduction of LDL cholesterol. Ezetimibe enables the reduction of the dose of statins and their putative toxicity and, in combination with statins, reduces CVD endpoints in CKD patients. The use of novel drugs such as PCSK9 inhibitors is safe in CKD, but their potential to reduce cardiovascular events in CKD needs to be elucidated in future studies.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30217 - Urology and nephrology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Current Atherosclerosis Reports
ISSN
1523-3804
e-ISSN
1534-6242
Volume of the periodical
26
Issue of the periodical within the volume
4
Country of publishing house
US - UNITED STATES
Number of pages
7
Pages from-to
103-109
UT code for WoS article
001150870300001
EID of the result in the Scopus database
2-s2.0-85183660070